Show simple item record

dc.contributor.authorAbu Zaid, M
dc.contributor.authorDinh, PC
dc.contributor.authorMonahan, PO
dc.contributor.authorFung, C
dc.contributor.authorEl-Charif, O
dc.contributor.authorFeldman, DR
dc.contributor.authorHamilton, RJ
dc.contributor.authorVaughn, DJ
dc.contributor.authorBeard, CJ
dc.contributor.authorCook, R
dc.contributor.authorAlthouse, S
dc.contributor.authorArdeshir-Rouhani-Fard, S
dc.contributor.authorSesso, HD
dc.contributor.authorHuddart, R
dc.contributor.authorMushiroda, T
dc.contributor.authorKubo, M
dc.contributor.authorDolan, ME
dc.contributor.authorEinhorn, LH
dc.contributor.authorFossa, SD
dc.contributor.authorTravis, LB
dc.contributor.authorPlatinum Study Group
dc.date.accessioned2019-06-24T09:41:21Z
dc.date.issued2019-05
dc.identifier.citationJournal of the National Comprehensive Cancer Network : JNCCN, 2019, 17 (5), pp. 459 - 468
dc.identifier.issn1540-1405
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3274
dc.identifier.eissn1540-1413
dc.identifier.doi10.6004/jnccn.2018.7109
dc.description.abstractBackground This study examined the prevalence of hypogonadism, its clinical and genetic risk factors, and its relationship to adverse health outcomes (AHOs) in North American testicular cancer survivors (TCS) after modern platinum-based chemotherapy.Patients and methods Eligible TCS were <55 years of age at diagnosis and treated with first-line platinum-based chemotherapy. Participants underwent physical examinations and completed questionnaires regarding 15 AHOs and health behaviors. Hypogonadism was defined as serum testosterone levels ≤3.0 ng/mL or use of testosterone replacement therapy. We investigated the role of 2 single nucleotide polymorphisms (rs6258 and rs12150660) in the sex hormone-binding globulin (SHBG) locus implicated in increased hypogonadism risk in the general population.Results Of 491 TCS (median age at assessment, 38.2 years; range, 18.7-68.4 years), 38.5% had hypogonadism. Multivariable binary logistic regression analysis identified hypogonadism risk factors, including age at clinical evaluation (odds ratio [OR], 1.42 per 10-year increase; P= .006) and body mass index of 25 to <30 kg/m2 (OR, 2.08; P= .011) or ≥30 kg/m2 (OR, 2.36; P= .005) compared with <25 kg/m2. TCS with ≥2 risk alleles for the SHBG SNPs had a marginally significant increased hypogonadism risk (OR, 1.45; P= .09). Vigorous-intensity physical activity appeared protective (OR, 0.66; P= .07). Type of cisplatin-based chemotherapy regimen and socioeconomic factors did not correlate with hypogonadism. Compared with TCS without hypogonadism, those with hypogonadism were more likely to report ≥2 AHOs (65% vs 51%; P= .003), to take medications for hypercholesterolemia (20.1% vs 6.0%; P<.001) or hypertension (18.5% vs 10.6%; P= .013), and to report erectile dysfunction (19.6% vs 11.9%; P= .018) or peripheral neuropathy (30.7% vs 22.5%; P= .041). A marginally significant trend for increased use of prescription medications for either diabetes (5.8% vs 2.6%; P= .07) or anxiety/depression (14.8% vs 9.3%; P= .06) was observed.Conclusions At a relatively young median age, more than one-third of TCS have hypogonadism, which is significantly associated with increased cardiovascular disease risk factors, and erectile dysfunction. Providers should screen TCS for hypogonadism and treat symptomatic patients.
dc.formatPrint
dc.format.extent459 - 468
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectPlatinum Study Group
dc.subjectHumans
dc.subjectTesticular Neoplasms
dc.subjectHypogonadism
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectNeoplasm Staging
dc.subjectOdds Ratio
dc.subjectRisk Factors
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectMale
dc.subjectGenetic Variation
dc.subjectYoung Adult
dc.subjectPatient Outcome Assessment
dc.subjectPatient Reported Outcome Measures
dc.subjectCancer Survivors
dc.titleAdverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.
dc.typeJournal Article
dcterms.dateAccepted2018-11-21
rioxxterms.versionofrecord10.6004/jnccn.2018.7109
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2019-05
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of the National Comprehensive Cancer Network : JNCCN
pubs.issue5
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.publication-statusPublished
pubs.volume17
pubs.embargo.termsNot known
icr.researchteamClinical Academic Radiotherapy (Huddart)en_US
dc.contributor.icrauthorHuddart, Roberten


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record